Compare PGY & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | PSNL |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2019 |
| Metric | PGY | PSNL |
|---|---|---|
| Price | $21.04 | $16.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $34.50 | $12.20 |
| AVG Volume (30 Days) | 2.0M | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.43 | 33.58 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,301,360,000.00 | $69,648,000.00 |
| Revenue This Year | $14.27 | $15.34 |
| Revenue Next Year | $14.39 | $41.46 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 26.07 | N/A |
| 52 Week Low | $10.40 | $4.96 |
| 52 Week High | $44.99 | $18.89 |
| Indicator | PGY | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 54.47 |
| Support Level | $20.50 | $7.62 |
| Resistance Level | $23.45 | $16.39 |
| Average True Range (ATR) | 1.14 | 0.61 |
| MACD | -0.29 | -0.21 |
| Stochastic Oscillator | 44.98 | 17.68 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.